Pfizer

₹4266.9 -32 | 0.7%

WEBSITE BSE:500680 NSE : PFIZER LTD. 10 May, 16:01

Market Cap ₹19520 Cr.

Stock P/E 37.3

P/B 5.7

Current Price ₹4266.9

Book Value ₹ 743.9

Face Value 10

52W High ₹4940

Dividend Yield 1.64%

52W Low ₹ 3729.9

Edit Ratio

Pfizer Research see more...

Overview Inc. Year: 1950Industry: Pharmaceuticals & Drugs

Pfizer Ltd is an India-based pharmaceutical agency. The Company has a portfolio of approximately 150 products across over 15 therapeutic areas. The Company is engaged in production, advertising, buying and selling and exporting pharmaceutical products. The Company gives various merchandise for anti-diabetic, erectile disorder, gastrointestinal (GI), multivitamins, anti-infectives, cardiovascular, dermatology, neurology, ache/fever/infection and autoimmune problems, amongst others. Its merchandise consist of Viagra, Daxid, Tricorex, Mucaine, Diamox, Hetrazan, Enbrel, Ativan, Pacitane, Folvite Tablets, Autrin Capsules, Prevenar 13, Wysolone, Loette, anti-infectives, cardiovascular, dermatology, Trulimax, Vibazime DT, Ovral G, Ovral L, Premarin pills, Premarin Vaginal Cream, Zosyn, Wymox, Tygacil, Cynomycin, Targit, Cyklokapron and Magnamycin. The Company has its personal production facility at Thane and Goa. The Company has numerous impartial settlement/third party manufacturers based throughout the country.

Pfizer Share Price

New

Volume

Price

Price: NSE50 DMA200 DMAVolume

Quarterly Price

Quarterly Monthly

Show Value Show %

Peer Comparison

Pfizer Quarterly Results

#(Fig in Cr.)	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Jun 2023	Sep 2023	Dec 2023
Net Sales	749	636	676	550	593	637	622	531	575	540
Other Income	12	15	18	17	18	24	27	33	36	36
Total Income	761	651	694	567	611	662	649	565	611	576
Total Expenditure	463	447	481	384	401	406	418	421	393	387
Operating Profit	298	204	213	183	210	256	231	144	219	188
Interest	2	2	2	4	4	3	4	3	3	3
Depreciation	27	27	27	34	27	26	26	16	15	18
Exceptional Income / Expenses	0	0	0	0	-136	189	0	0	0	8
Profit Before Tax	269	175	184	145	43	415	201	126	201	176
Provision for Tax	69	32	40	19	11	104	50	32	52	46
Profit After Tax	200	143	144	126	33	311	151	94	149	130
Adjustments	0	0	0	0	0	0	0	0	0	0
Profit After Adjustments	200	143	144	126	33	311	151	94	149	130
Adjusted Earnings Per Share	43.7	31.2	31.5	27.5	7.1	68	32.9	20.4	32.6	28.4

Pfizer Profit & Loss

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	TTM
Net Sales	1049	1112	1853	2012	1966	1969	2082	2152	2239	2611	2425	2268
Other Income	105	109	72	87	101	114	167	184	81	63	101	132
Total Income	1154	1221	1925	2099	2067	2083	2249	2336	2320	2674	2526	2401
Total Expenditure	865	873	1474	1579	1616	1468	1516	1579	1526	1775	1616	1619
Operating Profit	289	349	451	520	451	615	733	757	794	899	910	782
Interest	2	1	2	1	2	1	2	11	15	11	13	13
Depreciation	8	8	131	58	63	66	71	103	109	115	106	75
Exceptional Income / Expenses	414	0	-80	10	130	0	0	0	0	0	33	8
Profit Before Tax	694	340	238	470	517	548	660	642	669	773	824	704
Provision for Tax	191	119	138	165	180	188	231	133	171	160	200	180
Profit After Tax	503	221	100	305	337	360	429	509	498	613	624	524
Adjustments	0	0	-31	0	0	0	0	0	0	0	0	0
Profit After Adjustments	503	221	70	305	337	360	429	509	498	613	624	524
Adjusted Earnings Per Share	168.6	74	21.9	66.7	73.6	78.7	93.8	111.3	108.8	133.9	136.4	114.3

Growth Rates

#	1 Year	3 Year	5 Year	10 Year
Sales CAGR	-7%	4%	4%	9%
Operating Profit CAGR	1%	6%	8%	12%
PAT CAGR	2%	7%	12%	2%

#	1 Year	3 Year	5 Year	10 Year
Share Price CAGR	13%	-7%	7%	13%
ROE Average	21%	20%	18%	18%
ROCE Average	28%	27%	25%	26%

Pfizer Balance Sheet

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Shareholder's Funds	1694	658	1973	2163	2419	2683	3011	3395	2393	2864	3207
Minority's Interest	0	0	0	0	0	0	0	0	0	0	0
Borrowings	0	0	3	3	0	0	0	0	0	0	0
Other Non-Current Liabilities	-26	-19	-37	64	62	52	37	136	85	136	38
Total Current Liabilities	351	303	609	658	780	954	892	873	774	853	657
Total Liabilities	2020	942	2547	2888	3261	3690	3940	4405	3252	3854	3903
Fixed Assets	26	20	944	925	867	917	854	942	865	841	749
Other Non-Current Assets	190	237	350	331	343	357	371	415	479	616	629
Total Current Assets	1804	686	1252	1614	2033	2403	2702	3013	1873	2361	2493
Total Assets	2020	942	2547	2888	3261	3690	3940	4405	3252	3854	3903

Pfizer Cash Flow

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Opening Cash & Cash Equivalents	866	1433	308	488	71	68	51	74	1764	151	63
Cash Flow from Operating Activities	-16	132	113	345	329	332	98	323	427	667	356
Cash Flow from Investing Activities	626	103	-89	-701	-250	-238	35	1530	-469	-575	-36
Cash Flow from Financing Activities	-43	-1360	-1	-62	-83	-110	-110	-164	-1571	-181	-346
Net Cash Inflow / Outflow	567	-1125	23	-417	-3	-17	23	1690	-1613	-88	-26
Closing Cash & Cash Equivalent	1433	308	488	71	68	51	74	1764	151	63	37

Pfizer Ratios

#	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Earnings Per Share (Rs)	168.62	74.01	21.93	66.67	73.61	78.7	93.78	111.29	108.77	133.89	136.38
CEPS(Rs)	171.31	76.68	50.59	79.33	87.37	93.18	109.39	133.85	132.68	159.03	159.44
DPS(Rs)	32.5	360	12.5	15	20	20	22.5	330	35	30	70
Book NAV/Share(Rs)	567.81	220.64	431.28	472.92	528.72	586.49	658.22	742.18	523.07	626.1	701.05
Core EBITDA Margin(%)	16.8	20.54	19.69	20.67	17.15	25.28	27.17	26.62	31.82	30.79	31.6
EBIT Margin(%)	63.46	29.24	12.43	22.53	25.41	27.71	31.79	30.37	30.56	28.86	32.71
Pre Tax Margin(%)	63.3	29.15	12.36	22.47	25.31	27.67	31.7	29.86	29.87	28.46	32.18
PAT Margin (%)	45.91	18.96	5.21	14.57	16.49	18.18	20.61	23.66	22.23	22.56	24.37
Cash Profit Margin (%)	46.65	19.64	12.01	17.33	19.58	21.53	24.04	28.46	27.12	26.79	28.49
ROA(%)	28.24	14.91	5.75	11.22	10.95	10.36	11.25	12.2	13	17.24	16.09
ROE(%)	33.56	18.77	7.63	14.75	14.7	14.11	15.07	15.89	17.19	23.3	20.55
ROCE(%)	46.38	28.96	18.19	22.78	22.62	21.49	23.22	20.38	23.62	29.78	27.56
Receivable days	47.27	49.42	31.59	26.35	22.58	24.43	28.62	29.15	22.89	16.89	20.98
Inventory Days	58.01	49.61	51.1	65.25	61.01	57.05	59.95	69.32	70.57	59.41	61.77
Payable days	193.73	185.5	138.79	175.52	186.15	238.01	250.57	212.28	176.59	114.15	109.35
PER(x)	6.29	17.08	101.69	26.8	25.71	27.77	35.41	36.17	41.57	32.5	25.4
Price/Book(x)	1.87	5.73	5.17	3.78	3.58	3.73	5.04	5.42	8.64	6.95	4.94
Dividend Yield(%)	3.07	28.48	0.56	0.84	1.06	0.92	0.68	8.2	0.77	0.69	2.02
EV/Net Sales(x)	1.65	3.12	5.18	3.55	3.63	4.18	6.38	7.53	8.74	7	5.77
EV/Core EBITDA(x)	5.98	9.94	21.28	13.76	15.82	13.38	18.12	21.4	24.67	20.33	15.37
Net Sales Growth(%)	9.27	6	66.69	8.58	-2.29	0.11	5.74	3.37	4.04	16.64	-7.13
EBIT Growth(%)	170.82	-51.02	-29.69	96.98	9.96	5.76	20.59	-1.23	4.68	14.54	6.88
PAT Growth(%)	196.97	-56.11	-54.57	203.95	10.43	6.92	19.16	18.66	-2.26	23.1	1.86
EPS Growth(%)	196.97	-56.11	-70.36	203.95	10.42	6.92	19.16	18.66	-2.26	23.1	1.86
Debt/Equity(x)	0	0	0	0	0	0	0	0	0	0	0
Current Ratio(x)	5.14	2.26	2.06	2.45	2.61	2.52	3.03	3.45	2.42	2.77	3.79
Quick Ratio(x)	4.67	1.76	1.42	1.9	2.19	2.21	2.6	2.96	1.87	2.24	3.16
Interest Cover(x)	401.51	310.56	158.68	337.93	264.69	712.57	384.67	59.36	44.45	73.23	62.13
Total Debt/Mcap(x)	0	0	0	0	0	0	0	0	0	0	0

Pfizer Shareholding Pattern

#	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Promoter	63.92	63.92	63.92	63.92	63.92	63.92	63.92	63.92	63.92	63.92
FII	2.13	2.2	2.55	2.55	2.77	2.8	2.81	2.82	3.03	3.32
DII	15.02	15.06	14.83	14.88	14.93	14.9	14.89	15.01	15.15	15.33
Public	18.92	18.82	18.7	18.65	18.38	18.38	18.38	18.25	17.9	17.42
Others	0	0	0	0	0	0	0	0	0	0
Total	100	100	100	100	100	100	100	100	100	100

#	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Promoter	2.92	2.92	2.92	2.92	2.92	2.92	2.92	2.92	2.92	2.92
FII	0.1	0.1	0.12	0.12	0.13	0.13	0.13	0.13	0.14	0.15
DII	0.69	0.69	0.68	0.68	0.68	0.68	0.68	0.69	0.69	0.7
Public	0.87	0.86	0.86	0.85	0.84	0.84	0.84	0.83	0.82	0.8
Others	0	0	0	0	0	0	0	0	0	0
Total	4.57	4.57	4.57	4.57	4.57	4.57	4.57	4.57	4.57	4.57

Pros

Debtor days have improved from 114.15 to 109.35days.
Company is almost debt free.

Cons

Stock is trading at 5.7 times its book value.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Pfizer News

IPO

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Pfizer

Add Watchlist

Pfizer Research see more...

Overview Inc. Year: 1950Industry: Pharmaceuticals & Drugs

Pfizer Share Price

Alert Data

Quarterly Price

Peer Comparison

Pfizer Quarterly Results

Pfizer Profit & Loss

Growth Rates

Pfizer Balance Sheet

Pfizer Cash Flow

Pfizer Ratios

Pfizer Shareholding Pattern

Pfizer News

IPO

Stocx: India's #1 Marketplace to Find Your Winning Stock

Please Login!

Error!